SCHEMBL4518905

SCHEMBL4518905

CC(=O)c1c(C)[nH]c(O)cc1=O

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.44
CYP1A2 P05177 2/20 0.44
HSD17B10 Q99714 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
MEN1 O00255 1/20 0.39
HPGD P15428 1/20 0.39
KMT2A Q03164 1/20 0.39
GLA P06280 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
MAPT P10636 4/20 0.38
BRD4 O60885 4/20 0.38
BRPF1 P55201 2/20 0.38
CREBBP Q92793 2/20 0.38
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
THRB P10828 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
EP300 Q09472 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3188766 0.82 CYP1A2 (0.45) CYP3A4CYP1A2HSD17B10SMN1; SMN2HPGD
SCHEMBL3180881 0.76 HSD17B10 (0.49) CYP3A4CYP1A2HSD17B10SMN1; SMN2GLA
SCHEMBL13403037 0.74 BAZ2B (0.37) HSD17B10HPGDGLATHRB
SCHEMBL29025896 0.70 CYP1A2 (0.61) CYP3A4CYP1A2HSD17B10SMN1; SMN2MEN1
SCHEMBL7379657 0.69 CYP1A2 (0.45) CYP3A4CYP1A2HSD17B10SMN1; SMN2HPGD
SCHEMBL10686284 0.65 NOTUM (0.45) CYP3A4CYP1A2HSD17B10SMN1; SMN2HPGD
SCHEMBL4519599 0.65 ALDH1A1 (0.61) SMN1; SMN2MEN1KMT2AMAPTNPSR1
SCHEMBL8145766 0.64 CYP1A2 (0.67) CYP3A4CYP1A2HSD17B10SMN1; SMN2MEN1
SCHEMBL17788 0.64 MAPT (0.43) CYP3A4CYP1A2HSD17B10SMN1; SMN2MEN1
SCHEMBL2279251 0.64 KDM4E (0.62) CYP3A4SMN1; SMN2MEN1HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143368-A1 Use of Cinnamoyl Compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-06-04 US disclosed
EP-1857104-A1 USE OF CINNAMOYL COMPOUND Sumitomo Chemical Company, Limited (JP) 2007-11-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143368-A1 Use of Cinnamoyl Compound COL2A1, COL1A1, SMAD2 CYP3A4 4053/4885CYP1A2 3090/4885HSD17B10 1080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.